VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (RCEL) (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound ...

RCEL grew its portfolio with Cohealyx and RECELL GO Mini and effectively increased its TAM by over $2 billion. Deferred purchases from Q4 2024 should help Q1 2025 figures, which positions RCEL shares ...

(RTTNews) - AVITA Medical, Inc. (RCEL), a regenerative medicine company focused on innovative wound care solutions, announced that the U.S. Food and Drug Administration has approved its premarket ...

Avita Medical said the U.S. Food and Drug Administration has approved the company's premarket approval supplement for Recell Go mini, a system to treat smaller wounds. The Recell Go mini is a line ...

Earnings call AVITA Medical reported Q1 2025 revenue of $18.5M, up 67% YoY, fueled by the launch of ReCell Go Mini and Cohealyx. Despite a $13.9M net loss, the company reaffirmed FY25 revenue guidance ...

Cantor Fitzgerald reiterates an Overweight rating on Avita Medical (RCEL) following the company receiving FDA premarket approval for RECELL GO Mini, its miniaturized device designed to treat smaller ...